Pillai Arun Kumar
Known title: DirectorCIK: 0001717437
Associated companies
Transaction History
| OTLK | ▼ Sell | Other | 2,500,000 | $3.1M | 2/1/2022 | View on chart |
| OTLK | ▼ Sell | Other | 2,500,000 | $3.1M | 2/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kodiak Sciences stock rises on trial success
Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.
Kodiak Sciences stock rises on trial success. Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.